Therefore, this study aims to explore the molecular mechanism of QG in inhibiting HSC activation and playing an anti-liver fibrosis role in NAFLD transformation by using transforming growth factor-β1 (TGF-β1)-induced HSC model in vitro and CCl4 injection or HFHCD-treated liver fibrosis model in vivo. This evidence concerns the gene TGFB1 and Hepatic fibrosis.